top of page

 OUR PUBLICATIONS 

2025

Regulatory workshop on standardisation of clinical procedures, endpoints and data robustness of human challenge studies - A stakeholder meeting report.

Meln I, Cnossen V, Corti N, Andeweg A, Baay M, Chiu C, Coia J, Cornely O, Cox RJ, Dasyam D, De Keersmaecker SCJ, Deming M, Waldock J, Engelhardt OG, Guo M, Haj-Ali Saflo O, Hensen A, Jeeninga R, Kolstoe S, Krut O, Kuijper EJ, Leal L, Mazur N, Mohn KGI, Morel S, Osterhaus A, Moreira AP, Smits WK, Sridhar S, Toomey D, van Gerven J, Vehreschild MJGT, Yarzabal JP, Zimmer-Harwood P, Neels P, Olesen OF, Roestenberg M, Kamerling IMC.

Biologicals. 2025 Jan 16;90:101818.

2025

Safety, Tolerability, and Immunogenicity of the InvaplexAR-DetoxShigella Vaccine Co-Administered with the dmLT Adjuvant in Dutch and Zambian Adults: Study Protocol for a Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase Ia/b Clinical Trial.

Roozen GVT, Sukwa N, Chirwa M, White JA, Estrada M, Maier N, Turbyfill KR, Laird RM, Suvarnapunya AE, Sayeh A, D'Alessio F, Marion C, Pattacini L, Hoogerwerf MA, Murugan R, Terrinoni M, Holmgren JR, Sirima SB, Houard S, Simuyandi M, Roestenberg M.

Vaccines (Basel). 2025 Jan 8;13(1):48.

2024

Boosting Vaccine Research: The 16-Year Journey of TRANSVAC Vaccine Infrastructure.

Martin W, Luís C, Jungbluth S, Slezak M, Verreck FAW, Spiegel H, Guzman CA, Roldão A, Carrondo MJT, Van der Ley P, Segalés J, Dockrell HM, Ho MM, Pedersen GK, Lawrenz M, Olesen OF.

Vaccines (Basel). 2024 Dec 22;12(12):1446

2024

Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials.

Venkatraman N, Tiono AB, Bowyer G, Bellamy DG, Stockdale LK, Powlson J, Collins KA, Coulibaly S, Datoo MS, Silman D, Ouedraogo A, Nébié I, Imoukhuede EB, Brod F, Folegatti P, Dickinson-Craig E, Jamieson S, Bougouma EC, Wright D, Diarra A, Bliss CM, Morter R, Glenn G, Fries LF, Reimer JM, Lövgren-Bengtsson K, Baker M, Poulton I, Moyle S, Berrie E, Green N, Mukhopadhyay E, Viebig NK, Angus B, Lawrie A, Roberts R, Gilbert SC, Lewis DJM, Sirima SB, Ewer KJ, Hill AVS.

Lancet Microbe. 2024 Dec 17:100868.

2024

The AMR Accelerator: from individual organizations to efficient antibiotic development partnerships

Fernow J, Olliver M, Couet W, Lagrange S, Lamers MH, Olesen OF, Orrling K, Pieren M, Sloan DJ, Vaquero JJ, Miles TJ, Karlén A.

Nat Rev Drug Discov. 2024 Sep 23.

2024

Robust and persistent B-cell responses following SARS-CoV-2 vaccine determine protection from SARS-CoV-2 infection.

Byrne J, Gu L, Garcia-Leon A, Gaillard CM, Saini G, Alalwan D, Tomás-Cortázar J, Kenny G, Donohue S, Reynolds B, O'Gorman T, Landay A, Doran P, Stemler J, Koehler P, Cox RJ, Olesen OF, Lelievre JD, O'Broin C, Savinelli S, Feeney ER, O'Halloran JA, Cotter A, Horgan M, Kelly C, Sadlier C, de Barra E, Cornely OA, Gautier V, Mallon PW.

Front Immunol. 2024 Sep 17;15:1445653.

2024

Low Rates of Immunity among Medical Students and Residents in the Era of the Resurgence of Measles.

Ferrari C, Somma G, Caputi V, Treglia M, Pallocci M, Cenko F, Buonomo E, Carestia M, Di Giampaolo L, Olesen OF, Coppeta L.

Pathogens. 2024 Sep 11;13(9):784.

2024

How to develop a controlled human infection model for Clostridioides difficile.

Hensen ADO, Vehreschild MJGT, Gerding DN, Krut O, Chen W, Young VB, Tzipori S, Solbach P, Gibani MM, Chiu C, de Keersmaecker SCJ, Dasyam D, Morel S, Devaster JM, Corti N, Kuijper EJ, Roestenberg M, Smits WK.

Clin Microbiol Infect. 2024 Aug 29:S1198-743X(24)00425-7.

2024

How to develop a controlled human infection model for Clostridioides difficile.

Hensen ADO, Vehreschild MJGT, Gerding DN, Krut O, Chen W, Young VB, Tzipori S, Solbach P, Gibani MM, Chiu C, de Keersmaecker SCJ, Dasyam D, Morel S, Devaster JM, Corti N, Kuijper EJ, Roestenberg M, Smits WK.

Clin Microbiol Infect. 2024 Aug 29:S1198-743X(24)00425-7.

2024

Breadth of Fc-mediated effector function correlates with clinical immunity following human malaria challenge.

Nkumama IN, Ogwang R, Odera D, Musasia F, Mwai K, Nyamako L, Murungi L, Tuju J, Fürle K, Rosenkranz M, Kimathi R, Njuguna P, Hamaluba M, Kapulu MC, Frank R. CHMI-SIKA study team; Osier FHA.

Immunity. 2024 Jun 11;57(6):1215-1224.e6.

bottom of page